UPDATE: Sequenom, GSK Team to Create SNP Assay Portfolio

Aug 29, 2001

NEW YORK, Aug. 29 – Sequenom has begun the first phase of a research partnership with British drug giant GlaxoSmithKline to create a human genome-wide SNP assay portfolio to help them identify genes responsible for disease states and drug reaction, the companies said on Wednesday.

The deal calls for GlaxoSmithKline to be given access to Sequenom’s SNP assay portfolio. The pharmaceutical company then plans to select SNP candidates for genome-wide association studies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Quickly, Quickly

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Twisting the Results

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

'Right to Try' Heads Toward Law

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

This Week in Genome Research

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Main menu